Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 clinical trial evaluating the efficacy and safety of ART-001 in patients with slow-flow vascular malformations
jRCT2071210027Phase 2Completed
- Sponsor
- ARTham Therapeutics, Inc.
- Start
- Aug 2021
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of ART001 in slow-flow vascular malformation, venous malformation (VM), lymphangioma and 1 more (2 arms), sponsored by ARTham Therapeutics, Inc. Primary endpoint: Proportion of participants with response at Week 24. Started Aug 2021; status: completed.
02
Drugs
ART001
03
Conditions
slow-flow vascular malformationvenous malformation (VM)lymphangiomaKlippel-Trenaunay syndrome (KTS)
Beyond the preview
Go deeper on jRCT2071210027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210027.